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A B S T R A C T
Background
Cystic fibrosis is an inherited condition resulting in thickened, sticky respiratory secretions. Respiratory failure, due to recurrent
pulmonary infection and inflammation, is the most common cause of mortality. Muco-active therapies (e.g. dornase alfa and nebulized
hypertonic saline) may decrease sputum viscosity, increase airway clearance of sputum, reduce infection and inflammation and improve
lung function. Thiol derivatives, either oral or nebulized, have shown benefit in other respiratory diseases. Their mode of action is likely
to differ according to the route of administration. There are several thiol derivatives, and it is unclear which of these may be beneficial
in cystic fibrosis.
Objectives
To evaluate the efficacy and safety of nebulized and oral thiol derivatives in people with cystic fibrosis.
Search methods
We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group Trials Register, comprising references identified from com-
prehensive electronic database searches, hand searches of relevant journals, abstract books and conference proceedings.
Most recent search: 08 October 2010.
Selection criteria
Randomized and quasi-randomized controlled trials comparing nebulized or oral thiol derivatives to placebo or another thiol derivative
in people with cystic fibrosis.
Data collection and analysis
The authors independently assessed trials for inclusion, analysed methodological quality and extracted data.
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Main results
Searches identified 18 trials; eight (seven older than 10 years) (234 participants) are included. Three trials of nebulized thiol derivatives
were identified (one compared 20% n-acetylcysteine to 2% n-acetylcysteine; another compared sodium-2-mercaptoethane sulphonate
to 7% hypertonic saline; and another compared glutathione to 4% hypertonic saline). Although generally well-tolerated with no
significant adverse effects, there was no evidence of significant clinical benefit in our primary outcomes in participants receiving these
treatments.
Five studies of oral thiol derivatives were identified. Three studies compared n-acetylcysteine to placebo; one compared n-acetylcysteine,
ambroxol and placebo; and one compared carbocysteine to ambroxol. Oral thiol derivatives were generally well-tolerated with no
significant adverse effects, however there was no evidence of significant clinical benefit in our primary outcomes in participants receiving
these treatments.
Authors’ conclusions
We found no evidence to recommend the use of either nebulized or oral thiol derivatives in people with cystic fibrosis. There are very
few good quality trials investigating the effect of these medications in cystic fibrosis, and further research is required to investigate the
potential role of these medications in improving the outcomes of people with cystic fibrosis.
P L A I N L A N G U A G E S U M M A R Y
Compounds which can break down the structure of mucus for lung disease in cystic fibrosis
Cystic fibrosis is a genetic disorder which mainly affects the lungs. Chest infections recur in people with cystic fibrosis due to a build up
of thick sputum (phlegm) in the air passages. Several treatments, including thiol derivatives, aim to loosen this sputum and so improve
lung function and reduce the frequency of chest infections. Thiol derivatives may be either nebulized (breathed in) or oral (by mouth).
They have been shown to help in other lung conditions, such as chronic obstructive pulmonary disease. This review aims to find out
if there is enough evidence to recommend the nebulized or oral thiol derivatives for people with cystic fibrosis. We included eight
trials; three assessed the effect of nebulized thiol derivatives. Of the nebulized studies, one compared 20% n-acetylcysteine to 2% n-
acetylcysteine; another compared sodium-2-mercaptoethane sulphonate to 7% hypertonic saline; and the other compared glutathione
to 4% hypertonic saline. Nebulized thiol derivatives were generally well-tolerated with no major adverse effects. However they showed
no significant improvements in any of our outcome measures.
Five included studies assessed the effects of oral thiol derivatives.Three of these studies compared oral n-acetylcysteine to placebo; one
compared oral n-acetylcysteine, oral ambroxol and placebo; and one compared oral carbocysteine and oral ambroxol (no placebo).
None of the studies showed an overall significant benefit in any of the outcome measures of this review. Oral thiol derivatives were
generally well-tolerated with no major adverse effects.
In summary, the studies included in the review did not provide any evidence that nebulized or oral thiol derivatives were either beneficial
or harmful to people with cystic fibrosis. Further research investigating the effects of thiol derivatives in people with cystic fibrosis is
required before their use can be recommended.
B A C K G R O U N D
Description of the condition
Cystic fibrosis (CF) is a genetic multisystem disorder characterized
by thick, tenacious secretions resulting in organ damage, primarily
involving the lungs and gastrointestinal system. Over the past 30
years, survival in CF has increased dramatically due to the devel-
opment of new therapies and aggressive nutritional supplementa-
tion (CFF 2007; Corey 1996). Despite these improvements, the
most common cause of death is end-stage pulmonary disease and
respiratory failure (Davis 2006). Lung damage occurs secondary
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to the excessive inflammatory response to bacteria that reside in
the airways. The influx of neutrophils and stimulation of mu-
cus secretion within the airways results in thick secretions which
are difficult to clear. Furthermore, tenacious secretions adhere to
the airways worsening mucociliary clearance and ciliary function.
This creates an environment of increased bacterial burden, further
inflammation, and thicker secretions.
Description of the intervention
Mucolytic therapy has been proposed as a method to decrease spu-
tum viscosity, increase airway clearance of sputum, reduce bacte-
rial load and inflammation, improve lung function, and ultimately
increase survival (Henke 2007). It is typically initiated as part of
the ongoing treatment regimen and the effects of such therapies
are typically seen after regular use for a minimum of four weeks of
treatment. Several mucolytic therapies are available for use in CF
including dornase alfa (also known as rhDNase (Pulmozyme®))
(Fuchs 1994), hypertonic saline (Elkins 2006) and thiol derivatives
such as n-acetylcysteine (NAC) (Duijvestijn 1999). Macrolides
have been shown to affect mucus hypersecretion (Shimizu 2003)
but are considered mucoregulatory rather than mucolytic agents.
TheCochrane systematic reviews of both dornase alfa (Jones 2003)
and hypertonic saline (Wark 2005) have demonstrated an im-
provement in lung function and a reduction in the need for an-
tibiotic therapy for pulmonary exacerbations of CF. It is unclear
whether thiol derivatives result in the same beneficial effects.
Thiol derivatives are compoundswhich contain a functional group
of a sulfur atom and a hydrogen atom. This sulfhydryl group en-
ables thiol derivatives to break down the gel structure of mucus, by
substituting sulfhydryl groups for the disulfide bonds connecting
mucin proteins (Dasgupta 1996). NAC is the classic thiol deriva-
tive, but several other compounds are included under this head-
ing, including glutathione (GSH), cysteine, nacystelyn (NAL),
sodium-2-mercaptoethane sulphonate, carbocysteine, erdosteine
and mecysteine. In vitro, NAC has been demonstrated to reduce
the viscosity and elasticity of mucus when directly in contact with
airway secretions (Sheffner 1964). This may make sputum easier
to clear; however, thinner secretions could potentially be harder
to expectorate due to this reduced viscosity. NAC is a very acidic
compound (pH 2.2), and when inhaled results in airway irritation,
induction of cough and bronchospasm. Manufacturers therefore
suggest that individuals receive pre-treatment with a bronchodila-
tor prior to inhalation. It has been suggested that induction of
cough by inhaled NAC, rather than mucolysis, may explain any
beneficial effect of NAC on expectoration. This mechanism may
reduce airway inflammation by improving clearance of the pro-in-
flammatory neutrophil breakdown products of which CF sputum
largely consists. NAL, a lysine salt of NAC, has an approximately
neutral pH and is well-tolerated when inhaled (App 2002). When
studied in vitro, NAL has been demonstrated to have a more po-
tent mucolytic activity than NAC, and, also in vitro, has an ad-
ditional inhibitory effect on human neutrophil elastase (Marriott
1993).
How the intervention might work
Nebulized thiol derivatives
NAC is a very acidic compound (pH2.2), andwhen inhaled results
in airway irritation, induction of cough and bronchospasm. Man-
ufacturers therefore suggest that individuals receive pre-treatment
with a bronchodilator prior to inhalation. It has been suggested
that induction of cough by inhaled NAC, rather than mucolysis,
may explain any beneficial effect of NAC on expectoration. This
mechanism may reduce airway inflammation by improving clear-
ance of the pro-inflammatory neutrophil breakdown products of
which CF sputum largely consists. NAL, a lysine salt of NAC, has
an approximately neutral pH and is well-tolerated when inhaled
(App 2002). When studied in vitro, NAL has been demonstrated
to have a more potent mucolytic activity than NAC, and, also
in vitro, has an additional inhibitory effect on human neutrophil
elastase (Marriott 1993).
Oral thiol derivatives
Orally-administered thiol derivatives are proposed to work by a
different mechanism to inhaled thiol derivatives. Inhalation of
thiol derivatives aims to deliver the compound to the lower airway
in an attempt to act directly on airway secretions as a mucolytic.
However, when administered orally there is no detectable NAC
in bronchoalveolar lavage (Cotgreave 1987). Therefore orally-ad-
ministered thiol derivatives are unlikely to have a direct effect as
a mucolytic. Oral NAC is broken down (deacetylated) to cys-
teine, whose thiol group has reducing and antioxidant properties
(Bonanomi 1980). Neutrophils in the CF airway cause damage
by releasing oxidants, and are deficient in GSH, an important
endogenous cellular antioxidant. High-dose oral NAC increases
neutrophil GSH levels, decreases airway neutrophil recruitment
and reduces neutrophilic release of airway elastase (Tirouvanziam
2006a). The sulfhydryl group also allows NAC to interact directly
with oxidants, functioning as an oxidant scavenger (Ventresca
1989). Therefore, orally-administered thiol derivatives most likely
act by reducing pulmonary oxidative stress and inflammation,
and subsequently attenuating airway and parenchymal destruc-
tion. NAC also prevents inactivation of alpha-1-antitrypsin by
neutrophil elastase in vitro, and could also prevent lung damage in
CF by this mechanism (Borregaard 1987). In addition, oral thiol
derivatives may have a mechanism of action in reducing airway
inflammation by regulating redox signalling (Rahman 2006).
It must be stressed that the characteristics of CF sputum are dif-
ferent to that of sputum seen in other pulmonary diseases, such
as chronic obstructive pulmonary disease (COPD). CF sputum
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contains low levels of mucin, and consists predominantly of pus
derived from neutrophil degradation (Henke 2004). This obser-
vation may impact on the ability of inhaled thiol derivatives to
reduce sputum viscosity in CF, since mucin is their primary target.
In summary, inhaled thiol derivatives are proposed to act primarily
by their mucolytic effects, whereas when orally administered these
compounds are more likely to act predominantly as antioxidants,
with also a possible anti-inflammatory effect. These potential dif-
fering mechanisms of action are supported by in vitro evidence.
Different pharmacokinetics, mechanisms of action and adverse ef-
fects can be expected depending on the thiol derivative utilized,
the dose used, and the mode of administration.
Why it is important to do this review
The aim of this review is to collate and analyse the results of
randomized controlled trials (RCTs) examining the clinical (in
vivo) effects of both inhaled andoral thiol derivatives in the therapy
of lung disease in people with CF.We thereby aim to provide clear
evidence-based guidance regarding their effectiveness and safety
in this group of individuals.
O B J E C T I V E S
The aims of this review are to:
1. evaluate efficacy of both inhaled and oral thiol derivatives in
people with CF.
2. evaluate safety of both inhaled and oral thiol derivatives in
people with CF.
M E T H O D S
Criteria for considering studies for this review
Types of studies
All published and unpublished randomized and quasi-randomized
controlled trials. There was no language restriction for this review.
Types of participants
All individuals diagnosed with CF based on standard diagnostic
criteria (sweat testing or genetics and clinical features or family
history) were included. There were no restrictions on pulmonary
disease severity, gender, or pancreatic status.
Types of interventions
Studies investigating thiol derivatives given at any dose or fre-
quency, via nebulized or oral administration, for a minimum
of four weeks duration were eligible for inclusion. We felt four
weeks to be the minimum amount of time needed to see an
effect from the treatment. Outcomes for participants who re-
ceived thiol derivatives were compared to participants receiving
no treatment or to control groups including placebo or any other
medication. Nebulized and oral interventions were considered
separately in this review. Thiol derivatives considered for inclu-
sion were acetylcysteine (or N-acetylcysteine), sodium-2-mercap-
toethane sulphonate, carbocysteine, erdosteine, nacystelyn, glu-
tathione, cysteine and mecysteine.
Types of outcome measures
The following outcomes were recorded separately for both nebu-
lized and oral thiol derivatives.
Primary outcomes
1. Pulmonary function testing (PFT)
i) forced expiratory volume in one second (FEV1) per
cent predicted (change from baseline and absolute data)
ii) forced vital capacity (FVC) per cent predicted (change
from baseline and absolute data)
Secondary outcomes
1. Other PFT measurements which reflect airflow obstruction
or gas trapping or both, e.g. peak expiratory flow (PEF), vital
capacity (VC), FEV1/VC, mid-expiratory flow 25-75
(MEF25−75), residual volume/total lung capacity (RV/TLC)
(change from baseline and absolute data)
2. Inflammatory markers (change from baseline)
i) serum (white blood cell (WBC), C-reactive protein
(CRP), erythrocyte sedimentation rate (ESR))
ii) sputum (IL-8)
3. Quality of life (QOL) (change from baseline as measured
by a validated QOL scale)
4. Need for oral antibiotics for pulmonary exacerbation
i) number of weeks of treatment
ii) number of courses
5. Need for intravenous antibiotics for pulmonary
exacerbation
i) number of weeks of treatment
ii) number of courses
6. Adverse events
7. Number of days in hospital for respiratory exacerbation
8. Adherence
9. Acquisition of new respiratory pathogens (%)
10. Six-minute walk distance
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11. Sputum characteristics (including measures of viscosity and
elasticity)
Search methods for identification of studies
Electronic searches
We identified relevant trials using the Cystic Fibrosis Trials Regis-
ter using the terms: n-acetylcysteine OR ((acetylcysteine OR car-
bocysteine OR erdosteine ORmecysteine OR nacystelyn OR glu-
tathione OR cysteine OR sodium-2-mercaptoethane sulphonate)
AND (oral OR nebulised OR unstated)).
The Cystic Fibrosis Trials Register is compiled from electronic
searches of the Cochrane Central Register of Controlled Trials
(Clinical Trials) (updated each new issue ofThe Cochrane Library),
quarterly searches of MEDLINE, a search of EMBASE to 1995
and the prospective handsearching of two journals - Pediatric Pul-
monology and the Journal of Cystic Fibrosis. Unpublished work was
identified by searching the abstract books of three major cystic
fibrosis conferences: the International Cystic Fibrosis Conference;
the European Cystic Fibrosis Conference and theNorth American
Cystic Fibrosis Conference. For full details of all searching activi-
ties for the register, please see the relevant sections of the Cystic
Fibrosis and Genetic Disorders Group Module.
Date of last search: 08 October 2010.
Data collection and analysis
We used RevMan software to conduct the statistical analysis (
RevMan 2008).
Selection of studies
Two authors (EN, AS) assessed the articles identified against the
inclusion criteria for this review in an independent fashion.Where
possible, authors contacted primary investigators if any details
were unclear. They resolved any disagreements by discussion and
advice from the other co-authors.
Data extraction and management
Two authors (EN, AS) extracted data from the articles in an inde-
pendent fashion. Where possible, authors contacted primary in-
vestigators if their methodology was unclear. They resolved any
disagreements by discussion and advice from the other co-authors.
Where possible we grouped outcome data into those measured
at one month, up to three months, up to six months, up to
twelve months and then annually thereafter. If outcome data were
recorded at other time periods we examined these as well.
One of the included trials is a three-arm trial, and we are including
it in two comparisons (oral thiols versus placebo and oral thiols
versus other oral agents) (Ratjen 1985). By so doing, we realize
that some participants will be counted twice in this review.
Assessment of risk of bias in included studies
The authors assessed the articles for methodological quality to es-
tablish the risk of bias in each study using a component approach
and recorded details such as method of randomization, conceal-
ment of allocation, blinding and whether or not the data were
assessed using an intention-to-treat analysis (Jüni 2001). Where
possible, authors contacted primary investigators if their method-
ology was unclear.
Measures of treatment effect
When assessing differences between groups, we recorded themean
difference from baseline for each group as our treatment effect
measure for continuous variables. Where applicable, we calculated
a pooled estimate of treatment effect by calculating the mean dif-
ference (MD) and the 95% confidence intervals (CIs).
With binary outcomes, we planned to use the risk ratio (RR) and
the 95% CIs as a measure of treatment effect; however, we were
only able to present results using continuous data.
Unit of analysis issues
We included both parallel group trials as well as trials with a cross-
over design. Ideally we would have liked to analyse cross-over
trials using techniques outlined by Elbourne (Elbourne 2002);
however, due to limitations on the data available we were only
able to treat these trials as parallel trials and present data for the
end of treatment. We realise that this approach is conservative as it
ignores within-patient correlation and so does not make use of the
advantages of the cross-over design. Also, this approach ignores
the fact that patients appear in both arms of the trial and are not
independent of each other (Elbourne 2002). We did not combine
the data from cross-over trials with parallel trials as we were unable
to employ the methods recommended by Curtin (Curtin 2002).
For longitudinal data, we reported the time-points that measure-
ments were taken by the primary investigators and which mea-
sures were reported in the papers. In the review we present data
from end of treatment. We preferred to report data for the change
from baseline at end of treatment, but if the original paper re-
ported only absolute data (means, standard deviations (SD) of
groups or raw data), we planned to calculate the mean difference
and the variance of the difference imputed using the Follmann
method (Follmann 1992). This method allows the use of separate
sources of incomplete information to help choose a better vari-
ance estimate. This method can be summarised by the formula:
Var(change) = Var(pre-test) + Var(post-test) - 2 x SD(pre-test) x
SD(post-test) x pre-test-post-test correlation coefficient. We also
planned to report these absolute values post-treatment. Where the
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correlation coefficient was unknown we estimated it to be 0.4 (a
moderate correlation) in order to perform the calculation.
Dealing with missing data
When possible, the authors (EN, AS) contacted primary investi-
gators if missing data were required.
Assessment of heterogeneity
We planned to assess the heterogeneity of the studies using the Q
test, with heterogeneity being considered to be present if theQ test
was statistically significant at the P < 0.10 level. When assessing
themagnitude of any heterogeneity present, we planned to use the
I2 statistic (Higgins 2003).
Assessment of reporting biases
We intended on assessing publication bias using a funnel plot;
however, there were insufficient studies (minimum of 10 required)
to conduct this analysis.
With regards to selective reporting of outcomes, we were unable
to compare the original trial protocols with the final published
papers; however, there did not appear to be any obvious omissions
to the outcomes reported on by the trial investigators.
Data synthesis
Where heterogeneitywas not present, we used a fixed-effectmodel;
however, if in future we establish moderate or high degrees of
heterogeneity, we will utilize a random-effects model.
Subgroup analysis and investigation of heterogeneity
Several thiol derivatives are available, and therefore we planned to
perform subgroup analysis for each compound. The dose of the
thiol derivative usedmay alter outcomes, and therefore we planned
to perform subgroup analysis according to dose. There were in-
sufficient studies to perform either of these subgroup analyses on
this occasion, but we plan to perform these analyses in a future
update of the review when we are able to combine a sufficient
number of trials to allow this. Clinically important outcomes vary
depending on gender, age and severity of lung disease (FEV1 70%
to 80% will be considered mild; 60% to 70% moderate; 50% to
60% moderately severe; 34% to 50% severe; and less than 34%
very severe (ATS 1991)), and therefore we also planned to perform
an analysis using these subgroups. We planned to analyze age and
lung function as continuous variables as well as categorical vari-
ables in an attempt to identify any high-risk groups. The degree of
airway inflammation may also impact on the response to therapy
with thiol derivatives, and therefore we also planned to perform
subgroup analysis according to whether the study was performed
during an acute pulmonary exacerbation or during a period of
disease stability. Again, there were insufficient studies to perform
these subgroup analyses in this review, but we plan to perform
these analyses in a future update where possible. Lung function
will be categorized according to ATS guidelines for disease severity
as described above (ATS 1991), and age will be categorized in 10-
year blocks where possible.
Sensitivity analysis
We intended to conduct a sensitivity analyses based on the
methodological quality of the studies in the review; however, there
were insufficient studies to proceed with this analysis.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies.
Results of the search
The search process identified 23 published research papers from
a variety of international journals. These papers referred to 18
separate studies, of which we were able to include eight studies
and we excluded the remaining 10 studies.
Included studies
Eight studies eligible for inclusion were identified; three studies
examined the effects of nebulized thiol derivatives (Bishop 2005;
Howatt 1966; Weller 1980) and five studies evaluated oral thiol
derivatives in people with CF (Caramia 1995; Mitchell 1982;
Ratjen 1985; Stafanger 1988; Stafanger 1989). Clinical details
regarding the participants, interventions and outcomes are given
in the table Characteristics of included studies.
Nebulized thiol derivatives
Three trials compared nebulized thiol derivatives to other neb-
ulized medications (Bishop 2005; Howatt 1966; Weller 1980).
There was considerable heterogeneity between studies and there-
fore data from only two of these studies could be pooled for anal-
ysis (Bishop 2005; Weller 1980); also, the number of outcomes
for which data could be pooled was very limited.
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Participants
All trials had small numbers of participants (between eight and
29 participants in each trial). Two trials included both adults and
children (Bishop 2005; Howatt 1966) and one trial included chil-
dren only (Weller 1980).
Trial Design
One trial was of parallel design (Bishop 2005) and two of the
trials were of cross-over design (Howatt 1966; Weller 1980). The
two cross-over trials both compared two treatment arms (Howatt
1966; Weller 1980 ). Only one of the cross-over trials contained
a washout period between treatment blocks (Weller 1980).
Duration of treatment blocks ranged from one month to two
months; duration of the trials ranged from two to four months.
Interventions
One of the included studies assessed the effects of nebulized NAC
(Howatt 1966), another assessed the effects of nebulized sodium-
2-mercaptoethane sulphonate (Weller 1980) and the final study
assessed the effects of nebulized glutathione (Bishop 2005). Since
different thiol derivatives can be expected to have different clini-
cal effects, it is not appropriate to combine the results of studies
assessing different compounds.
None of the trials compared the effects of nebulized thiol deriva-
tives against a true placebo.TheHowatt study compared the effects
of nebulized 20% NAC and nebulized 2% NAC (it is unknown
whether nebulized 2% NAC has a clinical effect) (Howatt 1966).
The Weller study compared the effects of nebulized sodium-2-
mercaptoethane sulphonate and nebulized hypertonic (7%) saline
(Weller 1980) and the Bishop study compared nebulized glu-
tathione versus nebulized hypertonic saline (4%) (Bishop 2005).
Nebulized hypertonic saline, both at concentrations of 4% and
7%, has been demonstrated to have beneficial effects on the clini-
cal course of CF lung disease, so is not a true placebo (Wark 2005).
The number of daily treatments was different in all three trials; in
the Bishop trial there were four inhalations daily (Bishop 2005); in
the Howatt trial there were three inhalations daily (Howatt 1966);
and in the Weller trial there were twice daily inhalations (Weller
1980).
In the Howatt trial, participants either received the drug during
positive pressure breathing treatments or while using a Devilbiss
nebulizer (Howatt 1966).
Outcome measures
All three trials assessed pulmonary function at the end of treat-
ment, but used a variety of different measures (Bishop 2005;
Howatt 1966; Weller 1980). The Howatt paper only provides a
table outlining the number of pulmonary function tests which
improved or got worse compared to the previous month; however
there is insufficient detail in the table to ascertain which specific
pulmonary function tests improved (Howatt 1966). All of the
trials also reported baseline values (Bishop 2005; Howatt 1966;
Weller 1980).
Two trials asked participants to record cough frequency and spu-
tum volume and color (Bishop 2005; Weller 1980). In addition
Bishop asked participants to record general wellness and sputum
viscosity (Bishop 2005); and Weller asked participants to record
any adverse effects (Weller 1980).
One trial additionallymeasuredBMI and six-minutewalk distance
(Bishop 2005). Howatt evaluated participants clinically based on
the method of Shwachman and Kulczycki (Howatt 1966). Weller
additionally undertook blood tests (complete blood count, liver
function tests, renal function and electrolytes) and chest x-rays
(Weller 1980).
Oral thiol derivatives
Five trials reported on the effects of oral thiol derivatives; three of
the included trials reported on the effects of oral NAC compared
to placebo (Mitchell 1982; Stafanger 1988; Stafanger 1989); one
trial compared the effects of oral NAC, oral ambroxol and placebo
(Ratjen 1985); and the remaining trial compared the effects of
oral ambroxol and oral carbocysteine (Caramia 1995). Since the
Ratjen paper reports on a three-arm trial, and we are including
it in two comparisons (oral thiols versus placebo and oral thiols
versus other oral agents), we realize that some participants will be
counted twice in this review.
Participants
The number of participants in the trials ranged from20 to 52.One
trial experienced a high drop out rate (40%) (Stafanger 1989);
because of the unusually high dropout rate (which we will discuss
further under ’Risk of bias in included studies’) and the fact that
the results for only 10 participants out of 52 were presented in the
paper, we felt that this was unreliable data and therefore it was not
included in the analysis for this review.
One trial studied children only (Mitchell 1982), the others re-
cruited amixture of children and adults. All trials stated howmany
males and females were recruited and the proportions were ap-
proximately equal in all trials. All trials reported on clinical sta-
tus at randomization. Two trials recorded ‘mild to moderate pul-
monary disease’ (Mitchell 1982; Ratjen 1985); one trial recorded
good clinical status (Caramia 1995); two trials reported on colo-
nization with Pseudomonas aeruginosa (Stafanger 1988; Stafanger
1989). The earlier trial recruited participants who weren’t chron-
ically infected and the later trial recruited participants who were
chronically infected with Pseudomonas aeruginosa.
Trial Design
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Two trials were of parallel design (Caramia 1995; Ratjen 1985).
The other three trials were of cross-over design (Mitchell 1982;
Stafanger 1988; Stafanger 1989). Two trials described the use of a
washout period prior to the start of the intervention and between
interventions for cross-over trials (Mitchell 1982; Stafanger 1989).
A third cross-over trial does not state any washout period between
treatment arms (Stafanger 1988). The duration of each treatment
periodwas threemonths in four of the trials (Mitchell 1982;Ratjen
1985; Stafanger 1988; Stafanger 1989) and 80 days in the fifth
trial (Caramia 1995).
Interventions
Four trials compared oral NAC to placebo (Mitchell 1982; Ratjen
1985; Stafanger 1988; Stafanger 1989); one of these studies also
compared oral ambroxol to placebo (Ratjen 1985). Of the trials
comparing oral NAC to placebo, two trials stated that both active
and placebo drugs were given in granular form and could not be
distinguished from each other (Mitchell 1982; Ratjen 1985).Two
trials compared one oral thiol derivative to another oral thiol
derivative (Caramia 1995; Ratjen 1985) The first trial compared
oral carbocysteine syrup to oral ambroxol syrup (Caramia 1995)
and the second trial compared oral NACgranules to oral ambroxol
granules (Ratjen 1985).
Drugs were administered three times daily in all trials with the
following exceptions: in the trial of oral carbocysteine syrup versus
oral ambroxol syrup, the oral ambroxol syrup was given four times
daily to children under 14 years of age (Caramia 1995); in the
two trials by Stafanger, oral NAC was given twice daily if the
participant’s weight was over 30 kg (Stafanger 1988; Stafanger
1989).
Daily dosage of oral NAC was 200 mg three times daily in two
studies (Mitchell 1982; Ratjen 1985). The dose of NAC in both
Stafanger papers was 200 mg three times daily in participants
weighing less than 30 kg and 400 mg twice daily in participants
weighing more than 30 kg (Stafanger 1988; Stafanger 1989). The
dose of oral ambroxol was 30 mg three times daily in one study
(Ratjen 1985), and in the other study participants under 14 years of
age received 10mg four times daily and adults received 33mg three
times daily (Caramia 1995). The dosage of carbocysteine used in
the Caramia paper was 270 mg three times daily in participants
under 14 years of age and 900 mg three times daily in adults
(Caramia 1995).
Outcome measures
All trials measured outcomes at baseline and end of treatment
(Caramia 1995; Mitchell 1982; Ratjen 1985; Stafanger 1988;
Stafanger 1989). Four trials also measured outcomes in the in-
terim period: Caramia measured outcomes at 20, 40 and 60 days
(Caramia 1995); Ratjen measured outcomes at six weeks (but the
study only reports end of treatment data) (Ratjen 1985); both
Stafanger trials measured outcomes on a monthly basis (Stafanger
1988; Stafanger 1989).
All trials measured pulmonary function with a variety of outcome
measures, although the two Stafanger papers only reported results
for pulmonary function for 23 out of 41 participants (Stafanger
1988) and for 10 participants (whose baseline PEF was less than
70%predicted) out of 52 participants (Stafanger 1989). Four trials
assessed sputum characteristics (Caramia 1995; Mitchell 1982;
Stafanger 1988; Stafanger 1989). Three trials took blood samples:
Caramia performed an arterial blood gas analysis (Caramia 1995);
two trials measured white blood cell count, sedimentation rate and
antibody titres for Staphylococcus aureus, Pseudomonas aeruginosa,
andHemophilus influenza (Stafanger 1988; Stafanger 1989). Three
trials reported on adverse events (Caramia 1995; Mitchell 1982;
Ratjen 1985). Two trials reported on cough frequency (Caramia
1995; Mitchell 1982). Caramia additionally reported participants
subjective measurement of dyspnea (Caramia 1995) and Mitchell
additionally reported on antibiotic usage (Mitchell 1982).
Excluded studies
Ten trials were excluded because they did not meet the inclu-
sion criteria. Six trials were excluded as the duration of the inter-
vention was less than four weeks (App 2002; Gotz 1980; Griese
2004; Maayan 1989; Tecklin 1976; Snyder 2002); three trials
were excluded as they were not randomized (Dasgupta 1996;
Tirouvanziam 2006b, Dietzsch 1975); one trial was excluded as
the intervention was not relevant (Cezeaux 1967).
Risk of bias in included studies
The details of methodological quality of the reviewed studies are
given in the table Characteristics of included studies. The infor-
mation was extracted from the published papers.
Nebulized thiol derivatives
Three trials looked at nebulized thiol derivatives (Bishop 2005;
Howatt 1966; Weller 1980).
Allocation
All three trials were described as randomized; however, two of these
did not describe the randomization process and were therefore
deemed to have an unclear risk of bias (Bishop 2005;Weller 1980).
The Howatt trial randomized the order of drugs for the four-
month period by making up two slips of paper for each of the six
possible combinations; the participants then drew a schedule from
an envelope (Howatt 1966). The trial was deemed to have a low
risk of bias.
One trial does not clearly discuss allocation concealment and there-
fore it was judged to have an unclear risk of bias (Weller 1980).
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The other two trials do give details of adequate allocation conceal-
ment and were judged to have a low risk of bias (Bishop 2005;
Howatt 1966). Bishop reports that nomember of the clinical team
was involved in the generation of allocation to treatments (Bishop
2005). In the Howatt trial, the drugs were supplied in 10 ml vials
labelled with a letter code and the key to the code was supplied
in a sealed envelope, which was not opened until the study was
completed (Howatt 1966).
Blinding
All three trials were described as “double-blind” (Bishop 2005;
Howatt 1966;Weller 1980). Two of these trials described attempts
to mask the characteristics of the different treatments (e.g. taste
and odour) (Bishop 2005; Howatt 1966). These trials therefore
were deemed to have low risk of bias. The Weller trial made no
attempt to mask the characteristics of the different treatments and
was therefore judged to have a risk of bias (Weller 1980).
Incomplete outcome data
One trial reported data from all the randomized participants and
were therefore judged to have a low risk of bias (Howatt 1966).
Both the other two trials reported withdrawals (Bishop 2005;
Weller 1980). The numbers of drop outs in the are low and equal
across treatment groups, therefore these trials have a low risk of
bias.
One trial did not present data for all the participants randomized,
but did not discuss the reasons for this (Howatt 1966). This trial
is therefore judged to have a high risk of bias.
Weller did not report any data for FEV1 (Weller 1980). In re-
cently published trials it would be expected that this standard lung
function test would be measured at clinic visits and information
recorded. The lack of these data in a published paper could signal a
potential source of bias; it may have not been reported due to neg-
ative results. However, the trial in question is nearly 30 years old
and this measure of lung function may not have been employed
by the trialists.
Other potential sources of bias
TheHowatt trial has a number of potential sources of bias (Howatt
1966). Firstly, there is no washout period between treatments. Sec-
ondly, the drug delivery systemwas not consistent amongst all par-
ticipants. Two participants received the drug during positive pres-
sure breathing treatments while four participants used a Devilbiss
nebulizer. Thirdly, the paper provides a table outlining the number
of pulmonary function tests which improved or worsened com-
pared to the previous month; however, there is insufficient detail
in the table to ascertain which specific pulmonary function tests
improved. This is an important factor since certain pulmonary
function tests are clinically relevant and important outcomes to
measure, while other aspects of the testing can be highly variable
and difficult to interpret. And finally, the paper only provided
lung function data for two of the eight people in the trial (Howatt
1966).
Oral thiol derivatives
Five trials looked at oral thiol derivatives (Caramia 1995; Mitchell
1982; Ratjen 1985; Stafanger 1988; Stafanger 1989).
Allocation
All five trials were described as randomized; however, four of
the trials did not describe the randomization process and were
therefore deemed to have an unclear risk of bias (Caramia 1995;
Mitchell 1982; Stafanger 1988; Stafanger 1989). In the Ratjen
trial randomizationwas done by computer and the trial was judged
to have a low risk of bias (Ratjen 1985).
All five trials do not clearly discuss allocation concealment and
therefore were judged to have an unclear risk of bias (Caramia
1995; Mitchell 1982; Ratjen 1985; Stafanger 1988; Stafanger
1989).
Blinding
The Caramia trial was single-blinded, with investigators being
aware of the treatment allocation (Caramia 1995). This trial design
introduces a significant potential bias into the interpretation of
the results of this trial.
The other four trials were described as “double-blind” (Mitchell
1982; Ratjen 1985; Stafanger 1988; Stafanger 1989). Two of these
described attempts tomask the characteristics of the different treat-
ments (e.g. taste and odour); these trials therefore were deemed
to have low risk of bias (Mitchell 1982; Ratjen 1985). Neither of
other two trials which were described as double-blind discussed
any attempts to mask the characteristics of the different treatments
(e.g. taste and odour); these trials therefore have been judged to
have a potential risk of bias (Stafanger 1988; Stafanger 1989).
Incomplete outcome data
One trial reported data from all the randomized participants and
were therefore judged to have a low risk of bias (Caramia 1995).
We have attempted to contact Dr Caramia to obtain further data
relevant to his study, but as yet we have not had any reply. If we
obtain further data on this paper we plan to include this in a future
update of the review.
Two trials reportedwithdrawals (Mitchell 1982; Ratjen 1985), but
one of these does not give any reasons for the drop outs (Mitchell
1982). Mitchell does not give details of why the participants did
not complete the trial, nor does he state from which treatment
group they withdrew, so this trial has an unclear risk of bias (
Mitchell 1982). Also, the four withdrawals were not included in
the final analysis (Mitchell 1982). The numbers of drop outs in the
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Ratjen trial were low and equal across treatment groups, therefore
this trial has a low risk of bias (Ratjen 1985).
Two trials do not present data for all the participants randomized,
but do not discuss the reasons for this (Stafanger 1988; Stafanger
1989). There was an unusually high dropout rate in the later trial
where data for only 10 participants out of 52 were presented in
the paper (Stafanger 1989). These two trials are therefore judged
to have a high risk of bias.
Other potential sources of bias
Due to the limited amount of data reported in the Caramia paper
there is a risk of bias with regards to selective reporting (Caramia
1995).
One trial has a very serious potential risk of bias as some of the data
presented in the tables is incorrect (the data for total and mean
values in columns 5 and 6 in Table 2 of the final published paper
are not calculated correctly) (Stafanger 1989).
Two cross-over trials have a risk of bias due to either no washout
period between treatments (Stafanger 1988) or anunclear duration
of the washout period (Stafanger 1989).
Effects of interventions
Nebulized thiol derivatives versus other nebulized
medications
Primary outcomes
1. Pulmonary function testing (PFT)
a. forced expiratory volume in one second (FEV1) per cent
predicted
Two studies reported on this outcome (Bishop 2005; Howatt
1966), but we were only able to enter data into the analysis for one
trial (Bishop 2005). We have reported the results from the second
study narratively.
The data from the Bishop study showed no significant difference
in the change in FEV1 comparing participants receiving nebu-
lized glutathione and nebulized 4% saline, mean difference (MD)
0.90% (95% CI -6.45% to 8.25%) (Bishop 2005).
TheHowatt study reported no statistically significant difference in
FEV1 following periods when participants had received nebulized
20% NAC or nebulized 2% NAC (Howatt 1966).
b. forced vital capacity (FVC) per cent predicted
Two studies reported on this outcome (Bishop 2005;Weller 1980)
and we were able to enter data from both studies in the analysis
but did not combine the results since one trial was parallel and
one was cross-over. We found no significant difference between
treatment and control groups, in either the parallel trial MD 0.60
(95% CI -6.49 to 7.69) (Bishop 2005) or the cross-over trial MD
4.00 (95% CI -6.18 to 14.18) (Weller 1980).
Secondary outcomes
1. Other pulmonary function test (PFT) measurements
All three studies reported other PFTmeasurements (Bishop 2005;
Howatt 1966;Weller 1980), but only the Bishop andWeller study
presented data that we were able to enter into the analysis, again
not combined due to differences in trial design (Bishop 2005;
Weller 1980). The results for change in PEF were significant in
favour of nebulized thiol derivatives, MD 40.20 (95% CI 4.96 to
75.44) for the parallel trial (Bishop 2005), but not for the cross-
over trial, MD 9.00 (95% CI -3.66 to 21.66) (Weller 1980). We
were not able to combine data from any other PFTs (MEF25−75,
MEF50, Vmax50%VC, RV/TLC, vital capacity, peak inspiratory
flow) and none of the trials reported any significant differences
(Bishop 2005; Howatt 1966; Weller 1980). We have presented
data for: Vmax50%VC, MD 10.00 (95% CI -5.52 to 25.52) (
Weller 1980); forced expiratory flow, MD 6.20 (95% CI -6.79 to
19.19) (Bishop 2005); and RV/TLC, MD -4.00 (95% CI -16.11
to 8.11) (Weller 1980).
2. Inflammatory markers
a. serum (WBC, CRP, ESR)
None of the included studies reported on this outcome measure.
b. sputum (IL-8)
None of the included studies reported on this outcome measure.
3. Quality of life (QOL)
None of the included studies reported on this outcome measure.
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4. Need for oral antibiotics for pulmonary exacerbation
a. number of weeks of treatment
The Weller study reported that “courses of antibiotics were pre-
scribed as frequently during baseline periods as during either treat-
ment period”. There was no indication as to whether antibiotics
were oral or intravenous, and no details were supplied as to the
number of weeks or number of courses of antibiotics (Weller
1980).
None of the other included studies reported on antibiotic treat-
ment, either oral or intravenous.
b. number of courses
See comments above (in 4a) with regards to antibiotic therapy.
5. Need for intravenous antibiotics for pulmonary
exacerbation
a. number of weeks of treatment
See comments above (in 4a) with regards to antibiotic therapy.
b. number of courses
See comments above (in 4a) with regards to antibiotic therapy.
6. Adverse events
The nebulized thiol derivatives investigated in the included studies
were generally well-tolerated (Bishop 2005; Howatt 1966; Weller
1980).
The Bishop study reported no increased incidence of adverse ef-
fects in participants receiving nebulized glutathione compared
to nebulized 4% hypertonic saline (Bishop 2005). The Howatt
study reported that participants complained that nebulized NAC
“smelled and tasted bad”; and one participant in the same study
“complained of severe coughing attacks” while receiving nebulized
20% NAC “which would cause her to discontinue her treatment”
(Howatt 1966). Several participants in the Weller study “noted
that the inhalations initially made them cough, this occurring
equally at the start of both therapies, but usually settling within
days”, but that “no major adverse effects were noted during either
therapy” (Weller 1980). It should be noted that nebulized thiol
derivatives are used for their potential mucolytic properties, and
therefore increased cough is not necessarily an adverse effect.
7. Number of days in hospital for respiratory exacerbation
Only two studies reported on this outcome, but we were unable to
enter any data in the graphs (Bishop 2005; Weller 1980). Bishop
reported that “three patients were hospitalized ... due to non-im-
provement of conditions present at baseline”. Two of these par-
ticipants were receiving nebulized 4% saline and the other was
receiving nebulized glutathione. Weller reported that “three pa-
tients were admitted to hospital during the course of the trial ...
one of these was an inpatient for most of the trial. The other two
were admitted electively because of poor growth and persisting
respiratory symptoms, one during the initial baseline period and
one during the second month of saline treatment” (Weller 1980).
8. Adherence
Only one study reported on this outcome and stated that one par-
ticipant receiving nebulized glutathione “was grossly noncompli-
ant, ie, stopped the treatment after the first 5 days of the trial”.
No reason was given for this non-adherence, but the participant
was included in the modified ITT analysis (Bishop 2005).
9. Acquisition of new respiratory pathogens (%)
Only one study reported on this outcome (Weller 1980). It was
reported that there “was no change in sputum microbiology -
for example, appearance of Pseudomonas aeruginosa” between the
intervention groups (Weller 1980).
10. Six-minute walk distance
Only the Bishop study reported on this outcome (Bishop 2005).
There was no significant difference in 6-minute walk distance be-
tween participants receiving nebulized glutathione and nebulized
4% saline, MD 26.90m (95% CI -115.40m to 169.20m) (Bishop
2005).
11. Sputum characteristics
All three studies reported on this outcome (Bishop 2005; Howatt
1966; Weller 1980); but we were only able to enter data from one
study for sputum viscosity in the analysis (Bishop 2005).
Bishop reported no significant differences in sputum amount, vis-
cosity or color between the participants receiving nebulized glu-
tathione or nebulized 4% saline; we present data for sputum vis-
cosity, MD -0.40 (95% CI -1.53 to 0.73) (Bishop 2005).
The Howatt study reported that several participants noticed their
“sputum was thinner and it seemed easier to bring up” in both
groups (Howatt 1966).
The Weller reported “no significant differences in cough fre-
quency, sputum volume, or sputum colour on analysis” in either
group (Weller 1980).
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Oral thiol derivatives versus placebo
Primary outcomes
1. Pulmonary function testing (PFT)
a. forced expiratory volume in one second (FEV1) per cent
predicted
Three studies reported on this outcome (Ratjen 1985; Stafanger
1988; Stafanger 1989); however, we were only able to enter data
in the analysis from one of these studies (Ratjen 1985).
When entered into the analysis, data from the Ratjen study showed
no significant difference in FEV1, MD 5.00 per cent predicted
(95%CI -15.22 to 25.22) between those participantswho received
oral NAC compared to placebo.
In the earlier study, Stafanger reported no overall significant dif-
ference in FEV1 comparing participants receiving oral NAC and
those receiving placebo (Stafanger 1988).
In the later study, Stafanger reported no overall significant differ-
ence in FEV1 comparing periods when participants received oral
NAC and those when they received placebo (Stafanger 1989).
b. forced vital capacity (FVC) per cent predicted
Two studies reported on this outcome, but we were unable to enter
data into the analysis for either study (Stafanger 1988; Stafanger
1989).
In the 1988 study, Stafanger reported no overall significant dif-
ference in FVC comparing participants receiving oral NAC and
those receiving placebo (Stafanger 1988).
In the 1989 study, Stafanger also reported no overall significant
difference in FVC comparing periods when participants received
oral NAC and periods when they received placebo (Stafanger
1989).
Secondary outcomes
1. Other PFT measurements
All four studies reported a range of other PFT measurements (
Mitchell 1982; Ratjen 1985; Stafanger 1988; Stafanger 1989).
Two studies presented data that we were able to enter into the
analysis, but we were not able to combine these as they were used
different outcome measures (Mitchell 1982; Ratjen 1985).
Data from the Mitchell study show no significant difference in
PEF between the periods when participants received oral NAC
compared to when they received placebo, MD -3.00 (95% CI -
60.52 to 54.52) (Mitchell 1982).
Ratjen showed no significant difference in any measurements of
pulmonary function testing when participants received oral NAC
and placebo: PEF, MD 5.90 (95% CI -17.75 to 29.55); TLC,
MD -1.70 (95% CI -14.60 to 11.20); FVC75%, MD 15.90 (95%
CI -10.55 to 42.35); FVC50%, MD -7.90 (95% CI -36.87 to
21.07); FVC25%, MD -4.00 (95% CI -34.92 to 26.92); FEV1/
VC, MD 7.20 (95% CI -10.47 to 24.87); TGV, MD 4.20 (95%
CI -29.08 to 37.48); VC, MD -1.00 (95% CI -12.53 to 10.53);
and RV/TLC, MD -17.20 (95% CI -67.98 to 33.58)) (Ratjen
1985). Ratjen also reported no significant difference in airway
resistance, but we were not able to enter data into the analysis for
this outcome (Ratjen 1985).
In the 1988 study, Stafanger reported no significant difference
in PEF between periods when participants received oral NAC
compared to periodswhen they received placebo (Stafanger 1988).
In the 1989 study, Stafanger reported no overall significant dif-
ference in PEF comparing periods when participants received oral
NAC and when they received placebo (Stafanger 1989).
Inflammatory markers
a. serum (WBC, CRP, ESR)
Only two studies reported on this outcome (Stafanger 1988;
Stafanger 1989). Both studies reported no difference in white
blood cell count or erythrocyte sedimentation rate between those
who received NAC and those who received placebo.
b. sputum (IL-8)
None of the included studies reported on this outcome measure.
3. Quality of life (QOL)
None of the included studies reported on this outcome measure.
4. Need for oral antibiotics for pulmonary exacerbation
a. number of weeks of treatment
Four studies reported on this outcome (Mitchell 1982; Ratjen
1985; Stafanger 1988; Stafanger 1989); but only one study pre-
sented datawhichwe could enter into our analysis (Mitchell 1982).
There is a high possibility that these data may be skewed since
people with CF who require antibiotics usually receive them for at
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least two weeks, but a small group of people who are more severely
infected will receive them for much longer.
Mitchell does not differentiate between the use of oral or intra-
venous antibiotic therapy, but states there was no significant dif-
ference between antibiotic treatment between participants in the
NAC group versus those in the placebo group, MD -0.40 weeks
(95% CI -2.98 to 2.18) (Mitchell 1982).
In the paper, Ratjen reported that “no patients needed intermittent
antibiotic therapy during the course of the trial” (Ratjen 1985).
Neither of the studies by Stafanger reported any difference in an-
tibiotic treatment between periods when the participants received
oral NAC or placebo (Stafanger 1988; Stafanger 1989). There was
no indication as to whether antibiotics were oral or intravenous,
and no details were supplied as to the number of weeks or number
of courses of antibiotics. It should be noted that all participants
in later study by Stafanger entered the study having recently com-
pleted a course of intravenous antibiotics (Stafanger 1989).
b. number of courses
See comments above (in 4a) with regards to antibiotic therapy.
5. Need for intravenous antibiotics for pulmonary
exacerbation
a. number of weeks of treatment
See comments above (in 4a) with regards to antibiotic therapy.
b. number of course
See comments above (in 4a) with regards to antibiotic therapy.
6. Adverse events
Three studies reported on this outcome (Mitchell 1982; Ratjen
1985; Stafanger 1989). Two of these studies did not report any ad-
verse effects in either treatment or control groups (Mitchell 1982;
Ratjen 1985). In the 1989 study, Stafanger reported that one in-
dividual developed Quincke’s oedema and one developed a rash
while receiving oral NAC (Stafanger 1989). In both participants
these adverse effects settled once oral NAC was stopped. Two par-
ticipants also developed abdominal pain, one while receiving oral
NAC and one receiving placebo (Stafanger 1989). A further par-
ticipant in this same study felt that “she coughed more frequently
and less productively with NAC and stopped the treatment”. All
of these participants were excluded from the study due to these
adverse effects (Stafanger 1989).
7. Number of days in hospital for respiratory exacerbation
Only one study reported on this outcome (Stafanger 1988). This
study reported that none of the participants receiving either oral
NAC or placebo were hospitalized during the study (Stafanger
1988).
8. Adherence
Three studies reported on this outcome (Ratjen 1985; Stafanger
1988; Stafanger 1989).
Ratjen reported that two participants dropped out of the study
due to “irregular drug intake” (Ratjen 1985). In the earlier study,
Stafanger reported that two participants were excluded due to
“poor co-operation”, but did not specify whether this reflected
poor adherence (Stafanger 1988). Similarly, in the 1989 study,
Stafanger reported that 10 participants were excluded due to “poor
co-operation”, but did not elaborate (Stafanger 1989).
9. Acquisition of new respiratory pathogens (%)
None of the included studies reported on this outcome measure.
10. Six-minute walk distance
None of the included studies reported on this outcome measure.
11. Sputum characteristics
All four studies required participants to complete subjective scores
of sputum characteristics whilst receiving the different interven-
tions (Mitchell 1982; Ratjen 1985; Stafanger 1988; Stafanger
1989).One of the included studies presented data for this outcome
measure (Stafanger 1988) and the other three studies reported
these results narratively (Mitchell 1982; Ratjen 1985; Stafanger
1989). None of the four studies reported significant differences
in these subjective scores of sputum characteristics between par-
ticipants receiving oral NAC and placebo (Mitchell 1982; Ratjen
1985; Stafanger 1988; Stafanger 1989). Ratjen also reported nar-
ratively that there were no significant differences in a subjective
score of sputum characteristics between participants receiving oral
ambroxol and placebo (Ratjen 1985).
Oral thiols derivatives versus other oral thiol
derivatives
Primary outcomes
1. Pulmonary function testing (PFT)
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a. forced expiratory volume in one second (FEV1) per cent
predicted
Two trials reported on this outcome (Caramia 1995; Ratjen 1985),
but only data from one trial was included in the analysis (Ratjen
1985). Ratjen showed no significant difference in FEV1 between
groups receiving oral NAC and oral ambroxol -4.20% (95% CI -
26.19% to 17.79%) (Ratjen 1985). Caramia presents data show-
ing the change from baseline, but not from both the treatment
and control groups, so we are unable to enter the data into the
analysis (Caramia 1995). Caramia also reported that there was no
significant difference in FEV1 between groups receiving oral car-
bocysteine and oral ambroxol (Caramia 1995).
b. forced vital capacity (FVC) per cent predicted
None of the included studies reported on this outcome measure
Secondary outcomes
1. Other PFT measurements
Two trials reported on a range of other PFTmeasurements and but
only data from one trial could be included in the analysis (Ratjen
1985).
The Ratjen paper showed no significant differences in other PFT
measurements between participants receiving oral NAC and oral
ambroxol: PEF, MD -0.60 (95% CI -22.21 to 21.01); TLC, MD
1.30 (95% CI -11.18 to 13.78); FVC75%, MD 6.00 (95% CI -
18.83 to 30.83); FVC50%, MD 0.00 (95% CI -30.02 to 30.02);
FVC25%, MD -4.10 (95% CI -37.74 to 29.54); FEV1/VC, MD
-0.90 (95% CI -15.70 to 13.90); TGV, MD 13.50 (95% CI -
13.92 to 40.92); VC, MD 2.80 (95% CI -12.75 to 18.35); and
RV/TLC, MD -11.50 (95% CI -82.21 to 59.21) (Ratjen 1985).
Data from the Caramia study found no significant differences in
TV, PEF, MEF25 or MEF75 between participants receiving oral
carbocysteine and oral ambroxol (Caramia 1995).
Inflammatory markers
a. serum (WBC, CRP, ESR)
None of the included studies reported on this outcome measure.
b. sputum (IL-8)
None of the included studies reported on this outcome measure.
3. Quality of life (QOL)
None of the included studies reported on this outcome measure.
4. Need for oral antibiotics for pulmonary exacerbation
a. number of weeks of treatment
None of the included studies reported on this outcome measure.
b. number of courses
None of the included studies reported on this outcome measure.
5. Need for intravenous antibiotics for pulmonary
exacerbation
a. number of weeks of treatment
None of the included studies reported on this outcome measure.
b. number of course
None of the included studies reported on this outcome measure.
6. Adverse events
The Caramia and Ratjen studies did not report any adverse effects
in participants receiving oral thiol derivatives (Caramia 1995;
Ratjen 1985).
7. Number of days in hospital for respiratory exacerbation
None of the included studies reported on this outcome measure.
8. Adherence
None of the included studies reported on this outcome measure.
9. Acquisition of new respiratory pathogens (%)
None of the included studies reported on this outcome measure.
10. Six-minute walk distance
None of the included studies reported on this outcome measure.
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11. Sputum characteristics
Ratjen reported no significant differences in a subjective score of
sputum characteristics between participants receiving oral NAC
and oral ambroxol (Ratjen 1985).
Caramia included a subjective score of sputum characteristics, but
also assessed sputum viscosity and elasticity objectively using an
oscillometric visco-elastometer (Caramia 1995). There was no dif-
ference in the subjective score between participants receiving oral
carbocysteine or oral ambroxol (Caramia 1995), and there were
also no differences in viscosity or elasticity between participants
receiving the two treatments (Caramia 1995).
D I S C U S S I O N
Summary of main results
There have been very few good quality studies investigating the
effects of nebulized or oral thiol derivatives in cystic fibrosis. The
eight included studies assessed different thiol derivatives and used
very different study designs.
For nebulized thiol derivatives, the included studies report no evi-
dence that any of the nebulized thiol derivatives have a significant
beneficial effect on the primary outcome measures of this review
(FEV1 per cent predicted and FVC per cent predicted). There
were conflicting results with regards to the effect of nebulized thiol
derivatives on other pulmonary function tests, but overall no con-
vincing evidence that they are of clinical benefit. There was also
no evidence of a beneficial effect of nebulized thiol derivatives on
any of the other secondary outcome measures in this review. In
summary, we have found no evidence to recommend that nebu-
lized thiol derivatives should be used in routine clinical practice
in patients with CF.
For oral thiol derivatives, the five included studies assessed three
different drugs, using different preparations (tablets, granules and
syrup) and doses (some using a fixed dose and some dosing accord-
ing to body weight). None of the included studies demonstrated
a significant benefit of oral thiol derivatives on any of the primary
or secondary outcome measures of this review.
Several methodological challenges were apparent during this re-
view. The vast majority of the studies included very small sam-
ple sizes and may have been underpowered. Although pulmonary
function testing was typically reported, the type of pulmonary
function testing was highly variable with some studies reporting
on percent predicted FEV1 while others reported the peak expi-
ratory flow measurements. This may represent selective report-
ing whereby only certain measurements were recorded in the fi-
nal papers and may be a source of potential bias. No studies were
powered to look at other clinically important outcomes such as
need for hospitalization, new acquisition of bacteria, or changes
in quality of life. Two of the larger studies had unacceptably high
dropout rates which raised significant questions as to the reliabil-
ity of the study results (Stafanger 1988; Stafanger 1989). Because
some groups of individuals with CF may respond more than oth-
ers, we had planned to do subgroup analyses for factors such as
severity of lung disease and age. None of the studies provided ad-
equate information on these subgroups, making it impossible to
carry out any subgroup analyses.
Overall completeness and applicability of
evidence
The included studies were generally complete, although the exclu-
sion criteria of the studies and the age range of the included par-
ticipants limits their applicability to the general CF population.
Quality of the evidence
The evidence on which this review is based is limited in terms of
the quantity and quality of included studies. In all eight studies the
generation of allocation sequences was stated as randomized, but
in only two of these (Howatt 1966; Ratjen 1985) was the method
of randomization adequate, as defined by Jüni (Jüni 2001). The
concealment of treatment allocation was unclear in six of the in-
cluded studies, with only two (Howatt 1966; Ratjen 1985) having
an adequate method of allocation concealment (Jüni 2001). Seven
of the eight included studies stated that they were double blinded,
with one stating that it was single blinded (Caramia 1995). Four
trials backedup this statementwith an explanationof how they had
masked the characteristics of the different interventions (Bishop
2005; Howatt 1966; Mitchell 1982; Ratjen 1985); but three trials
made no attempt to disguise the interventions (Stafanger 1988;
Stafanger 1989; Weller 1980). Additionally, in the ’placebo-con-
trolled’ studies assessing nebulized thiol derivatives, the placebo
intervention was either a weaker solution of the active interven-
tion, or was an active intervention in its own right (such as nebu-
lized hypertonic saline). In the case of nebulized hypertonic saline
the beneficial effect of this intervention has only been confirmed
in recent years and was not known to the investigators in the rel-
evant included studies.
Potential biases in the review process
One of the co-authors of this review, Professor Felix Ratjen, is lead
investigator on one of the included trials.
Agreements and disagreements with other
studies or reviews
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The results of this review are broadly in agreement with the sys-
tematic review of NAC in CF prepared by Duijvestijn and Brand
(Duijvestijn 1999).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
From this review of eligible trials, we have not been able to identify
any evidence to recommend the use of nebulized thiol derivatives
in people with CF.We have also not been able to find any evidence
to recommend the use of oral thiol derivatives in the management
of CF lung disease.
Implications for research
Despite the paucity of literature on the effectiveness of thiol deriva-
tives in CF, these are still potentially useful drugs for further study
because thickened mucous, leading to chronic infection and in-
flammation and respiratory failure is still the most common cause
of early death in CF. Therapies aimed at improving sputum clear-
ance and therefore reducing pulmonary infection and inflamma-
tion are sorely needed. The other effectivemucolytic therapies that
are available for pulmonary disease inCF are unable to be tolerated
by some people due to side effects (mainly bronchospasm) and
can also be prohibitively expensive (in the case of dornase alfa).
Thiol derivatives are relatively inexpensive, and, especially when
administered orally, are well-tolerated. Further studies are required
to investigate the potential beneficial effects of both nebulized and
oral thiol derivatives in CF lung disease.
Well-designed randomized placebo controlled double-blind trials
of people with CF over six years of age are required to adequately
assess the potential benefit of these medications. Pulmonary func-
tion testing cannot be reliably done in individuals under the age of
six years. A wide range of disease severities and age groups should
be included in these studies and in sufficient numbers so that data
on these subgroups can be analyzed separately. It is not clear from
the literature if mucolytic therapy is helpful in early disease to pre-
vent decline in lung function or whether it is more advantageous
later in the disease course when mucous production is increased.
Enrolling participants with a wide range of disease severity may
help to elucidate this. As mucolytic therapy takes time to exert
its effect, the duration of the trials should be no less than four
months, with six months of follow up to evaluate the long-term ef-
fects of therapywith thiol derivatives. Pulmonary function (specif-
ically FEV1 and FVC), would be reasonable primary endpoints,
while other secondary endpoints such asmarkers of inflammation,
need for both IV and oral antibiotics therapy, number of days in
hospital, quality of life, acquisition of new respiratory pathogens,
and radiologic improvement would be key in assessing the effi-
cacy of these medications. Mortality, although an important hard
endpoint, would not be recommended as an outcome measure as
it is unlikely changes in mortality would be detected in a 4 to 12
month trial given the median survival in CF at present.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Bishop 2005
Methods Randomized, double-blind, placebo-controlled study.
Single center in the USA.
8-week study period, with participants receiving the same intervention for the whole 8
weeks
A “modified” ITT analysis was carried out whereby all patient outcomes were included,
regardless of compliance, except when patients were hospitalized or were missing data
Participants Nineteen participants were recruited.
Mean age 13.1 years (range 6 - 19 years).
Stable clinical status with mild pulmonary disease.
Participants were paired by age and sex, and then each member of the pair was randomly
assigned to the treatment or placebo groups
One participant in the placebo group dropped out ’just before the trial began’, and was
not included in the analysis
Interventions Nebulized buffered reduced GSH versus nebulized placebo. GSH was buffered with
sodium bicarbonate and dosed at 66mg/kg body weight. Placebo was composed of
sodium chloride dosed at 15mg/kg body weight, and quinine at 25-30 µg/kg body
weight. Participants were instructed to self-administer their intervention medication
“across 4 inhalation sessions per day” and asked to “space these sessions 3- to 4-h apart”.
For the first week of the study, participants “were instructed to use one fourth of the
recommended total dosage, and in the second week to use one half of the recommended
total dosage. After the second week, patients were instructed to use the full daily total
dosage”
Outcomes Primary outcome measures: FEV1(% predicted), FVC (% predicted), FEF25−75 (%
predicted), PEF.
FEV1, FVC and FEF25−75 were measured once prior to starting the intervention period,
and once after completing the intervention period. PEF was measured by the participant
twice daily throughout the study
Secondary outcome measures:
Objective - BMI, 6-min walk distance (m).
These objective measures were recorded once prior to starting the intervention and once
after completing the intervention
Subjective:
• Sputum color (scale ranging from 1 = clear to 6 = blood streaked)
• Sputum amount (1=scant, 2 = <1 teaspoon), 3 = >1 teaspoon)
• Sputum viscosity (1 = very thin, 2 = slightly sticky, 3 = very sticky)
• Cough frequency (1 = no cough, 2 = infrequent, 3 = several times per day, 4 =
every hour)
• General wellness (1 = poor, 2 = fair, 3 = good, 4 = excellent)
• Usual stamina (1 = poor, 2 = fair, 3 = good, 4 = excellent)
• Improvement (1 = significantly worse, 2 = a bit worse, 3 = about the same, 4 = a
bit better, 5 = significantly better).
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Bishop 2005 (Continued)
The baseline measure for each of the subjective measures was taken as the ’average of the
first 5 days of the trial’, and the ’end of trial measure’ was taken as the ’average of last 5
days of the trial’
Adverse events.
Notes Paper states that in the analysis, ’differences between post-trial and baseline outcomes
were analyzed using GLMM that allowed for correlation between outcomes with the
age/sex pair used for randomization.’
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Randomization process not described.
Allocation concealment? Yes No member of the clinical team was in-
volved in the generation of the sequence of
allocation to treatments
Blinding?
Participants
Yes Trial described as “double-blind” and at-
tempts were made to mask the charac-
teristic odour of nebulized glutathione by
adding quinine to the 4%hypertonic saline
Blinding?
Clinicians/assessors
Yes Trial described as “double-blind” and at-
tempts were made to mask the charac-
teristic odour of nebulized glutathione by
adding quinine to the 4%hypertonic saline
Incomplete outcome data addressed?
All outcomes
Unclear Three individuals hospitalized during the
studywere excluded fromdata analysis, and
therefore data from nine participants re-
ceiving nebulized glutathione, and seven
participants receiving nebulized 4% hyper-
tonic saline were reported in the study
Free of other bias? Unclear No other sources of bias identified.
Caramia 1995
Methods Randomized, single-blind, parallel-group design.
Single center in Italy.
80-day intervention period.
ITT analysis was carried out, with all participants completing the trial and all their data
being analysed
Participants 26 CF participants (12 males).
Age range 8 - 26 years (mean (SE) 15.9 (1.7) years in the SCMS-Lys group, 16.2 (1.5)
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Caramia 1995 (Continued)
years in the ABX group)
Good clinical status (Schwachmann index 76.2 (2.8) in the SCMS-Lys group, 77.3 (3.
5) in the ABX group)
“Concomitant administration of antitussives, muco-actives, sedatives, H1-receptor an-
tagonists and systemic corticosteroids was not allowed during the study”
Interventions One group received SCMS-Lys at a dose of 900mg tid in adults and 270mg tid in
children under 14 years of age. The other group received oral ABX at dose of 33mg tid
in adults and 10 mg qid in children under 14 years of age
Outcomes At baseline, 20, 40, 60 and 80 days of the intervention period, participants had the
following assessments performed:
• Cough frequency, “intensity of dyspnoea/tachypnoea” and chest sound
abnormalities as assessed and rated on a 5-point digital scale (1 = greatest degree of
abnormality, 5 = absence of symptom or sign).
• Viscosity and elasticity of expectorated sputum as assessed by an “oscillometric
visco-elastometer”.
• Estimated sputum volume over the preceding 24-hour period was also rated (1 =
>50 mls/day, 2 = 25-50 mls/day, 3 = <25 mls/day, 4 = ’little or no expectorate’).
• Arterial blood gas analysis.
• Tidal volume, FEV1, PEF, MEF25, MEF50, MEF75 and ’Tiffeau index’.
• Assessment of adverse effects.
In addition, the Shwachmann score was assessed at baseline and at 80 days
Notes
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Randomization process not described.
Allocation concealment? Unclear Trial does not clearly discuss allocation con-
cealment.
Blinding?
Participants
Yes Single-blinded, with investigators being
aware of the treatment allocation
Blinding?
Clinicians/assessors
No Single-blinded, with investigators being
aware of the treatment allocation
Incomplete outcome data addressed?
All outcomes
Unclear All 26 participants completed the study
protocol anddata fromall participantswere
reported
Free of other bias? Unclear No other sources of bias identified.
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Howatt 1966
Methods Randomized, double-blind, controlled, cross-over design.
Single centre in USA.
4-month trial period, participants receiving interventions for 1 month at a time. No
washout period.
No dropouts.
Data was analysed by ITT, however only limited data was presented in the paper
Participants 8 CF participants (3 male).
Age range 6 - 22 years (mean 12.6).
Clinical status ranged from “excellent” to “moderate” (based on the method of Shwach-
man and Kulczycki).
4 participants stopped using nebulized isoproterenol, antibiotics, 3% saline during the
trial period, whereas the other 4 participants did not alter their pre-trial therapy.
None of the participants had ever received NAC before the trial
Interventions Nebulized 20% NAC tid, versus nebulized 2% NAC tid.
Outcomes Subjective improvement in sputum thickness and ability to expectorate, PFTs (VC, PEF,
PIF, E50, FEV1, SBO), adverse reactions.
Notes Participants had a total of 4 months of treatment but could receive it monthly as follows:
1st combo: 20%NAC then 2%NAC then 20%NAC then 2%NAC
2nd combo: 2%NAC then 20%NAC then 2%NAC then 20%NAC
3rd combo: 20%NAC then 20%NAC then 2%NAC then 2%NAC
4th combo: 2%NAC then 2%NAC then 20%NAC then 20%NAC
5th combo: 2%NAC then 20%NAC then 20%NAC then 2%NAC
6th combo: 20%NAC then 2%NAC then 2%NAC then 20%NAC
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Randomized order of drugs by making up
2 slips of paper for each of the 6 possible
combinations
Allocation concealment? Yes Drugs were supplied in 10 ml vials labelled
with a letter code and the key to the code
was supplied in a sealed envelope, which
was not opened until the study was com-
pleted
Blinding?
Participants
Yes Trial described as “double-blind” and at-
tempts were made to mask the characteris-
tic odour of the treatments by using differ-
ent concentrations of nebulized NAC
Blinding?
Clinicians/assessors
Yes Trial described as “double-blind” and at-
tempts were made to mask the characteris-
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Howatt 1966 (Continued)
tic odour of the treatments by using differ-
ent concentrations of nebulized NAC
Incomplete outcome data addressed?
All outcomes
Unclear 8 participants were entered into the trial,
but pulmonary function data is only re-
ported for 2 out of these 8
Free of other bias? Unclear Trial has a risk of bias due to nowashout pe-
riod between treatments. The drug delivery
system was not consistent amongst all par-
ticipants. 2 participants received the drug
during positive pressure breathing treat-
ments while 4 participants used a Devilbiss
nebulizer. A table is provided in the paper
outlining the number of PFTs which im-
proved or got worse compared to the pre-
vious month; however there is insufficient
detail in the table to ascertain which spe-
cific PFTs improved
Mitchell 1982
Methods Randomized, double-blind, placebo-controlled, cross-over study design.
Single centre in New Zealand.
Initial 2-week training period where all participants took placebo. Duration 6 months
(3 months in each limb, with a 2-week training period and a 2-week wash out period
when all participants took placebo)
Not ITT as 4 participants withdrew from the trial and were not included in final analysis
Participants 20 children (10 male) with CF.
Mean (SD) age 10.8 (5.9) years.
Stable mild to moderate pulmonary disease (mean (SD) Schwachman score 76 (10)).
Aerosolized mucolytic therapy was stopped during the trial period
Interventions 3 months on oral placebo and 3 months on 200 mg oral NAC tid
Outcomes Clinical assessment, body weight, CXR score, daily best-of-three PEF, antibiotic usage,
cough frequency (scale of 0 - 3), and self-assessed sputum viscosity (scale of 0 - 3).
Numerical results only provided for weight change, duration on antibiotics (not stated
whether oral or intravenous) and PEF
Notes
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Randomization process not described.
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Mitchell 1982 (Continued)
Allocation concealment? Unclear Trial does not clearly discuss allocation con-
cealment.
Blinding?
Participants
Unclear The study drugs were similar in appear-
ance and the study was described as being
“double-blind” with no specific details on
who was blinded. Both the active drug and
the placebo were made of orange flavoured
granules
Blinding?
Clinicians/assessors
Unclear The study drugs were similar in appear-
ance and the study was described as being
“double-blind” with no specific details on
who was blinded. Both the active drug and
the placebo were made of orange flavoured
granules
Incomplete outcome data addressed?
All outcomes
Unclear Four participants withdrew from the trial;
therefore, 16 were included in the final
analysis
Free of other bias? Unclear No other sources of bias identified.
Ratjen 1985
Methods Randomized, double-blind, placebo-controlled, parallel study design.
Single centre in Germany.
2-week washout period prior to starting treatment.
Duration 12 weeks.
Not ITT (4 participants dropped out and were not included in final analysis)
Participants 36 participants with CF (16 male).
Age 6 - 21 years (mean 13.9).
Mild to moderate lung disease.
Atopic individuals, and those on bronchodilators excluded.
Interventions 3 treatment arms. Oral NAC 200 mg tid, oral ABX 30 mg tid or placebo, each for 12
weeks
Outcomes PFTs (Raw, TGV, sRaw, REZ, VC, FEV1, FEV1/VC, V 75% FVC, V 50% FVC, V 25%
FVC, PEF, TLC, RV/TLC) recorded after washout period, at 6 weeks and 12 weeks.
PFTs reported as mean values as percentage of normal, with no absolute values reported.
After the study, parents and participants were asked whether they had improved, deteri-
orated or remained stable during the study, and if they thought that they had received a
drug or placebo during the trial
Notes
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Ratjen 1985 (Continued)
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Yes Computer-generated randomization.
Allocation concealment? Unclear Trial does not clearly discuss allocation con-
cealment.
Blinding?
Participants
Unclear The study drugs were similar in appearance
and the study was described as being “dou-
ble-blind” with no specific details on who
was blinded. Both the active drug and the
placebo were of granular appearance and
could not be distinguished with regard to
taste, colour or odour
Blinding?
Clinicians/assessors
Unclear The study drugs were similar in appearance
and the study was described as being “dou-
ble-blind” with no specific details on who
was blinded. Both the active drug and the
placebo were of granular appearance and
could not be distinguished with regard to
taste, colour or odour
Incomplete outcome data addressed?
All outcomes
Unclear 36 participants entered the trial with 4
withdrawals; therefore the final analysis was
on 32 participants. 4 participants did not
complete the study due to irregular drug
intake, missed clinic appointments, or clin-
ical deterioration
Free of other bias? Unclear No other sources of bias identified.
Stafanger 1988
Methods Randomized, double-blind, placebo-controlled, cross-over design.
Single centre in Denmark.
6 months on each intervention, followed by 3 months follow-up.
Not ITT as 3 participants were excluded from the final analysis
Participants 41 participants with CF (23 males).
Age 2 - 31 years (mean 9.5).
None were infected by Pseudomonas aeruginosa. Stable disease, but disease severity not
stated.
Exclusions: past history of peptic ulcer disease, liver or kidney disease and pregnancy
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Stafanger 1988 (Continued)
Interventions 3 periods, each 3 months duration. First period oral NAC (200mg tid if <30kg, 400mg
bid if >30kg) or placebo, then cross over to the other intervention, then 3 months follow
up
Outcomes Subjective scores of symptoms, body weight, sputum bacteriology and PFTs (FEV1,
FVC, PEF) recorded every month. 3-monthly serum WBC, ESR and Staphylococcal
aureus, Haemophilus influenzae and Pseudomonas aeruginosa antibody titres. Time on
antibiotics also recorded. Ciliary function was also studied (ciliary beat frequency and
ciliary beating pattern) in 20 participants
Notes
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Randomization process not described
Allocation concealment? Unclear Trial does not clearly discuss allocation con-
cealment.
Blinding?
Participants
Unclear Trial described as “double-blind” but no
details were given on who was blinded
Blinding?
Clinicians/assessors
Unclear Trial described as “double-blind” but no
details were given on who was blinded
Incomplete outcome data addressed?
All outcomes
Unclear Studied 44 participants in this trial, and
while 41 participants completed the study,
data on only 23 participants are presented
in the paper
Free of other bias? Unclear Trial has a risk of bias due to no washout
period between treatments
Stafanger 1989
Methods Randomized, double-blind, placebo-controlled, cross-over study design.
Single centre in Denmark.
2 periods of 3 months receiving either active drug or placebo.
All participants received intravenous antibiotics routinely on a 3-monthly basis, once
before starting the trial and again at the mid-point of the trial
Not ITT as 21 participants were excluded from the final analysis
Participants 52 participants with CF, with 31 (17 males) completing it.
Mean age 15 years (range 7 - 33).
All were chronically infected with Pseudomonas aeruginosa.
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Stafanger 1989 (Continued)
Lung function ranged from severely impaired to normal.
All pre-trial treatments continued during the trial.
Interventions OralNAC 200mg tid (< 30kg), oral NAC 400mg BD (> 30kg), or placebo (bicarbonate
tablets)
Outcomes Monthly ’subjective score’, body weight, sputum bacteriology and PFTs (FVC, FEV1,
PEF). Blood test for WBC, ESR and antibodies to Staphylococcal aureus, Haemophilus
influenzae and Pseudomonas aeruginosa at the start of the trial and at the end of each 3-
month period. Ciliary function also assessed
Notes
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Randomization process not described.
Allocation concealment? Unclear Trial does not clearly discuss allocation con-
cealment.
Blinding?
Participants
Unclear Trial described as “double-blind” but no
details were given on who was blinded
Blinding?
Clinicians/assessors
Unclear Trial described as “double-blind” but no
details were given on who was blinded
Incomplete outcome data addressed?
All outcomes
Unclear 52 individuals entered the trial, but only
31 completed the trial resulting in a 40%
dropout rate
The paper presents data only on a subgroup
of participants (n = 10) who have baseline
PEF < 70%. There is no data provided on
the remaining 21 participants
Free of other bias? Unclear Trial has a very serious potential risk of bias
as some of the data presented in the tables is
incorrect (the data for total and mean val-
ues in columns 5 and 6 in Table 2 are not
calculated correctly). There was also an un-
clear duration of the washout period. Par-
ticipants were also excluded from the study
due to adverse effects
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Weller 1980
Methods Randomized, double-blind, cross-over study.
Single centre in UK.
2-month baseline periods preceded and followed 2 intervention periods each lasting 8
weeks.
Not ITT as 2 participants were not included in the final analysis
Participants 29 children with CF. 27 children completed the trial (13 male).
Age 6 - 15 years (mean 10.7).
Disease severity not reported.
Interventions Nebulized 3 ml sodium 2-mercaptoethane sulphonate (Mistabron) 20% solution bid or
nebulized 3 ml 7% saline bid. Both nebulized from a Wright nebulizer operated by an
air compressor (8 litres/minute)
Outcomes Diary card record of post-physiotherapy sputum volume, sputum color and cough fre-
quency (recorded on a scale from 1 to 3). Sputum culture and PFTs (PEF, FVC, Vmax
50% VC and RV/TLC) taken every month. CXR (Crispin and Norman score), full
blood count, liver function tests, electrolytes and creatinine taken at the beginning and
end of the study period
Notes
Risk of bias
Item Authors’ judgement Description
Adequate sequence generation? Unclear Randomization process not described.
Allocation concealment? Unclear Trial does not clearly discuss allocation con-
cealment.
Blinding?
Participants
Unclear Trial described as “double-blind” but no
details were given on who was blinded. No
attempts were made to disguise the taste or
odour of the interventions
Blinding?
Clinicians/assessors
Unclear Trial described as “double-blind” but no
details were given on who was blinded. No
attempts were made to disguise the taste or
odour of the interventions
Incomplete outcome data addressed?
All outcomes
Unclear 2 children were withdrawn from the study
(one due to an acute pulmonary exacerba-
tion while receiving nebulized 7% hyper-
tonic saline and one due to non-compli-
ance), and therefore data for 27 children
are reported in the study
Free of other bias? Unclear No other sources of bias identified.
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ABX: ambroxol hydrochloride
BID: twice daily
CF: cystic fibrosis
CXR: chest X-ray
ESR: erythrocyte sedimentation rate
E50: forced flow rate when 50% of VC has been expired (synonymous with FEF50)
FEF50: forced expiratory flow at 50% of VC
FEV1: forced expiratory volume at one second
FVC: forced vital capacity
GSH: glutathione
ITT: intention to treat
MMEFR: maximum mid-expiratory flow rate
MMV: maximum voluntary ventilation
NAC: n-acetylcysteine
PEF: peak expiratory flow
PFT: pulmonary function test
PIF: peak inspiratory flow
QID: four times daily
Raw: upper airway resistance
REZ: oscillometric determination of airway resistance
RV: residual volume
SBO: small bowel obstruction
SCMS-Lys: oral carbocysteine lysine salt monohydrate
SD: standard deviation
sRaw: specific airways resistance
TGV: thoracic gas volume
TID: three times daily
TLC: total lung capacity
TV: Tidal volume
V 25% FVC: maximal expiratory flow in 25% vital capacity
V 50% FVC: maximal expiratory flow in 50% vital capacity
V 75% FVC: maximal expiratory flow in 75% vital capacity
VC: vital capacity
WBC: white blood cell
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
App 2002 Intervention period less than 4 weeks.
Cezeaux 1967 Intervention not applicable (bronchial lavage under general anaesthetic)
Dasgupta 1996 Non-randomized, in vitro study of the effects of rhDNase and NAL on sputum spinnability and rheology
Dietzsch 1975 Study not randomized.
Gotz 1980 Intervention period less than 4 weeks.
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(Continued)
Griese 2004 Intervention period less than 4 weeks.
Maayan 1989 Intervention period less than 4 weeks.
Snyder 2002 Intervention period less than 4 weeks.
Tecklin 1976 Intervention period less than 4 weeks.
Tirouvanziam 2006b Not a randomized controlled trial.
NAC: n-acetylcysteine
NAL: nacystelyn
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D A T A A N D A N A L Y S E S
Comparison 1. Nebulized thiols versus other nebulized medications
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Change in forced expiratory
volume in 1 second
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
1.1 Up to 3 months 1 Mean Difference (IV, Fixed, 95% CI) Not estimable
2 Change in forced vital capacity 2 Mean Difference (IV, Fixed, 95% CI) Totals not selected
2.1 Up to 3 months (parallel) 1 Mean Difference (IV, Fixed, 95% CI) Not estimable
2.2 Up to 3 months
(cross-over)
1 Mean Difference (IV, Fixed, 95% CI) Not estimable
3 Peak expiratory flow 2 Mean Difference (IV, Fixed, 95% CI) Totals not selected
3.1 Up to 3 months (parallel) 1 Mean Difference (IV, Fixed, 95% CI) Not estimable
3.2 Up to 3 months
(cross-over)
1 Mean Difference (IV, Fixed, 95% CI) Not estimable
4 Vmax50% Vital capacity 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
4.1 Up to 3 months 1 Mean Difference (IV, Fixed, 95% CI) Not estimable
5 Forced expiratory flow 25-75 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
5.1 Up to 3 months 1 Mean Difference (IV, Fixed, 95% CI) Not estimable
6 RV/TLC 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
6.1 Up to 3 months 1 Mean Difference (IV, Fixed, 95% CI) Not estimable
7 Six-minute walk test [metres] 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
7.1 Up to 3 months 1 Mean Difference (IV, Fixed, 95% CI) Not estimable
8 Sputum viscosity 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
8.1 Up to 3 months 1 Mean Difference (IV, Fixed, 95% CI) Not estimable
Comparison 2. Oral thiols versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Change in forced expiratory
volume in 1 second [%
predicted]
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
1.1 Up to 3 months 1 Mean Difference (IV, Fixed, 95% CI) Not estimable
2 Peak expiratory flow [L/min] 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
2.1 Up to 3 months 1 Mean Difference (IV, Fixed, 95% CI) Not estimable
3 Change in peak expiratory flow
[% predicted]
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
3.1 Up to 3 months 1 Mean Difference (IV, Fixed, 95% CI) Not estimable
4 Change in total lung capacity [%
predicted]
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
4.1 Up to 3 months 1 Mean Difference (IV, Fixed, 95% CI) Not estimable
31Nebulized and oral thiol derivatives for pulmonary disease in cystic fibrosis (Review)
Copyright © 2010 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
5 Change in flow 75% FVC [%
predicted]
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
5.1 Up to 3 months 1 Mean Difference (IV, Fixed, 95% CI) Not estimable
6 Change in flow 50% FVC [%
predicted]
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
6.1 Up to 3 months 1 Mean Difference (IV, Fixed, 95% CI) Not estimable
7 Change in flow 25% FVC [%
predicted]
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
7.1 Up to 3 months 1 Mean Difference (IV, Fixed, 95% CI) Not estimable
8 Change in forced expiratory
volume in 1 sec/vital capacity
[% predicted]
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
8.1 Up to 3 months 1 Mean Difference (IV, Fixed, 95% CI) Not estimable
9 Change in total gas volume [%
predicted]
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
9.1 Up to 3 months 1 Mean Difference (IV, Fixed, 95% CI) Not estimable
10 Change in vital capacity [%
predicted]
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
10.1 Up to 3 months 1 Mean Difference (IV, Fixed, 95% CI) Not estimable
11 Change in residual volume/total
lung capacity [% predicted]
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
11.1 Up to 3 months 1 Mean Difference (IV, Fixed, 95% CI) Not estimable
12 Antibiotic treatment [weeks] 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
12.1 Up to 3 months 1 Mean Difference (IV, Fixed, 95% CI) Not estimable
Comparison 3. Oral thiols versus other oral agents
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Change in forced expiratory
volume in 1 second [%
predicted]
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
1.1 Up to 3 months 1 Mean Difference (IV, Fixed, 95% CI) Not estimable
2 Change in peak expiratory flow
[% predicted]
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
2.1 Up to 3 months 1 Mean Difference (IV, Fixed, 95% CI) Not estimable
3 Change in total lung capacity [%
predicted]
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
3.1 Up to 3 months 1 Mean Difference (IV, Fixed, 95% CI) Not estimable
4 Change in flow 75% FVC [%
predicted]
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
4.1 Up to 3 months 1 Mean Difference (IV, Fixed, 95% CI) Not estimable
5 Change in flow 50% FVC [%
predicted]
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
5.1 Up to 3 months 1 Mean Difference (IV, Fixed, 95% CI) Not estimable
6 Change in flow 25% FVC [%
predicted]
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
6.1 Up to 3 months 1 Mean Difference (IV, Fixed, 95% CI) Not estimable
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